PTC Therapeutics’ exec VP sells $4 million in stock

Mark Elliott Boulding, Executive Vice President and Chief Legal Officer at PTC (NASDAQ:PTC) Therapeutics (NASDAQ:PTCT), executed a series of stock transactions on March 10 and 11, 2025. Boulding sold shares totaling approximately $4,003,304, with sale prices ranging from $52.24 to $53.15 per share. The sales occurred as the company’s stock trades near its 52-week high of $55.60, having delivered an impressive 66% return over the past year.

The transactions included multiple sales and exercises of stock options. Notably, Boulding exercised options to acquire shares at prices between $25.69 and $33.02, with the total value of these acquisitions amounting to $2,407,913. According to InvestingPro data, PTC Therapeutics maintains strong liquidity with a current ratio of 2.35, indicating healthy short-term financial positioning.

These transactions were conducted under a pre-established Rule 10b5-1 trading plan, which allows insiders to set up a predetermined schedule for buying or selling stock. This strategy is often used to avoid potential accusations of insider trading. For deeper insights into PTCT’s valuation and financial health metrics, including exclusive ProTips and comprehensive analysis, check out the detailed research report available on InvestingPro.

Following these transactions, Boulding’s direct ownership in PTC Therapeutics stands at 103,901 shares. The company, currently valued at $4.23 billion, appears slightly overvalued according to InvestingPro’s Fair Value analysis.

In other recent news, PTC Therapeutics reported its fourth-quarter 2024 earnings, revealing a slight miss in earnings per share (EPS) but meeting revenue expectations. The company posted an EPS of -$0.85, compared to the forecasted -$0.79, while revenue came in at $213 million, closely aligning with the anticipated $213.45 million. For the full year 2024, PTC Therapeutics achieved revenue of $877 million, exceeding its guidance. Cantor Fitzgerald maintained its Overweight rating on PTC Therapeutics, with a price target of $113, reflecting confidence in the company’s potential despite slightly lower revenue projections based on updated financial guidance for 2025.

Additionally, BofA Securities upgraded PTC Therapeutics from Underperform to Neutral, raising the price target to $55, influenced by the FDA’s expedited review of the company’s investigational drug vatiquinone for treating Friedreich’s ataxia. Meanwhile, Scotiabank (TSX:BNS) initiated coverage of PTC Therapeutics with a Sector Perform rating and a $55 price target, suggesting the stock is fairly valued in the market. These developments highlight the company’s ongoing efforts to navigate challenges and leverage opportunities in the rare disease treatment market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.